Proteologics

Discovering Cancer Inhibition Therapy

Health Tech & Life Sciences
Acquired (Inactive) by Zmiha Investment House Ltd. on Sep 2013 - closed due to acquisition

Company Overview

Snapshot

Founded in May 1999 by Uriel (Uri) Halavee and Gleb Zilberstein, Proteologics operated with 1–10 employees. The company raised $25 million across one funding round. A significant milestone occurred in September 2013 when Zmiha Investment House Ltd. acquired control of Proteologics.

Business overview

Proteologics Ltd. was a biopharmaceutical company focused on exploiting the ubiquitin system for the discovery and development of novel therapeutics for cancer treatment. The company's research identified correlations between ubiquitin pathway components and pathological conditions, leveraging the ubiquitin system for new therapies, primarily focusing on inhibitors for specific E3 ubiquitin ligases. Proteologics operated within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the pharmaceuticals market.

Strategic signal

In September 2013, Zmiha Investment House Ltd. acquired control of Proteologics Ltd. for NIS 12.1 million, purchasing 44.95% of the company from XTL Biopharmaceuticals Ltd. This acquisition led Proteologics to freeze its research activity, signaling a strategic shift from active drug discovery to a holding entity, with its stocks continuing to be traded on the TASE.

Company Intelligence Q&A

When was Proteologics founded and by whom?
Proteologics was founded in May 1999 by Uriel (Uri) Halavee and Gleb Zilberstein.
What was the primary focus of Proteologics' research?
Proteologics focused on exploiting the ubiquitin system for the discovery and development of novel therapeutics for cancer treatment, specifically identifying inhibitors for E3 ubiquitin ligases.
What was a key acquisition event for Proteologics?
In September 2013, Zmiha Investment House Ltd. acquired control of Proteologics Ltd. from XTL Biopharmaceuticals Ltd. for NIS 12.1 million.
What was the total capital raised by Proteologics?
Proteologics raised a total of $25 million across one funding round.
What was the status of Proteologics' research activity after the 2013 acquisition?
After Zmiha Investment House Ltd. acquired control in September 2013, Proteologics decided to freeze its research activity.

External links